Invention Grant
- Patent Title: Inhibition of PCSK9 through RNAI
-
Application No.: US15286948Application Date: 2016-10-06
-
Publication No.: US10167471B2Publication Date: 2019-01-01
- Inventor: Joanne Kamens , Anastasia Khvorova
- Applicant: RXi Pharmaceuticals Corporation
- Applicant Address: US MA Marlborough
- Assignee: RXi Pharmaceuticals Corporation
- Current Assignee: RXi Pharmaceuticals Corporation
- Current Assignee Address: US MA Marlborough
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: C12N15/85
- IPC: C12N15/85 ; C07H21/02 ; C07H21/04 ; C12N15/113

Abstract:
The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
Public/Granted literature
- US20170137823A1 INHIBITION OF PCSK9 THROUGH RNAI Public/Granted day:2017-05-18
Information query
IPC分类: